https://www.selleckchem.com/pr....oducts/Novobiocin-so
Adoptive immunotherapy with tumour-infiltrating lymphocytes (TIL) may benefit from the use of selective markers, such as PD-1, for tumour-specific T-cell enrichment, and the identification of predictive factors that help identify those patients capable of rendering tumour-reactive TILs. We have investigated this in ovarian cancer (OC) patients as candidates for TIL therapy implementation. PD-1 and PD-1 CD8 TILs were isolated from ovarian tumours and expanded cells were tested against autologous tumour cells. Baselin